{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T07:27:00Z","timestamp":1745220420568},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"9-10","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Male breast cancer (MBC) is rare and consequently understudied. Here we present the case of contralateral breast cancer in a male patient nearly a quarter century following his initial breast cancer diagnosis and treatment. The epidemiology, risk factors, diagnosis, characterization, treatment, and prognosis of male breast cancer are reviewed. MBC accounts for &amp;lt;1% of all breast cancer with an estimated incidence nearly 1.25 per 100,000 person years. Our patient tested positive for ATM mutation of undetermined significance. More commonly in males, a BRCA2 mutation confers a &amp;gt;1 in 15 lifetime risk of breast cancer and is present in &amp;gt;11% of MBC patients, while BRCA1 is present in an estimated &amp;lt;1.5% of MBC patients. The risk of contralateral breast cancer developing in a male with a unilateral lesion is much higher than for a primary male breast cancer in the general population. Men tend to be diagnosed at a later age and stage than females. Prognosis for male and female breast cancer is similar considering both age of patient and stage of the tumor at diagnosis, and similar treatment paradigms have resulted in similar outcomes. Although lumpectomy with radiation therapy may have the same prognosis as mastectomy, the standard of care for male breast cancer continues to be simple mastectomy with sentinel lymph node biopsy.<\/jats:p>","DOI":"10.1093\/milmed\/usz049","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T08:50:29Z","timestamp":1554195029000},"page":"e581-e586","source":"Crossref","is-referenced-by-count":2,"title":["Metachronous Contralateral Male Breast Cancer: Case Report and Literature Review"],"prefix":"10.1093","volume":"184","author":[{"given":"Thomas R","family":"O\u2019Leary","sequence":"first","affiliation":[{"name":"Department of Surgery, School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig D","family":"Shriver","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Wind","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"issue":"12","key":"2020011209063885700_usz049C1","first-page":"4452","article-title":"BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients","volume":"9","author":"Kwiatkowska","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2020011209063885700_usz049C2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/318181","article-title":"Variation in cancer risks, by mutation position, in BRCA2 mutation carriers","volume":"68","author":"Thompson","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"3","key":"2020011209063885700_usz049C3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10549-016-4085-4","article-title":"Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results","volume":"161","author":"Pritzlaff","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"2020011209063885700_usz049C4","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/ng1837","article-title":"ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles","volume":"38","author":"Renwick","year":"2006","journal-title":"Nat Genet"},{"issue":"3","key":"2020011209063885700_usz049C5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10549-016-4003-9","article-title":"Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care","volume":"160","author":"Graffeo","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"6D","key":"2020011209063885700_usz049C6","first-page":"4293","article-title":"Prevalence of Klinefelter\u2019s syndrome in male breast cancer patients","volume":"17","author":"Hultborn","year":"1997","journal-title":"Anticancer Res"},{"issue":"3","key":"2020011209063885700_usz049C7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10549-005-9074-y","article-title":"Breast cancer and long-term hormonal treatment of male hypogonadism","volume":"96","author":"Medras","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2020011209063885700_usz049C8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1515\/hmbci-2013-0022","article-title":"Paracrine and intracrine contributions of androgens and estrogens to adipose tissue biology: physiopathological aspects","volume":"14","author":"Waraich","year":"2013","journal-title":"Horm Mol Biol Clin Investig"},{"issue":"5","key":"2020011209063885700_usz049C9","first-page":"1326","article-title":"A case-control study of male breast cancer","volume":"48","author":"Casagrande","year":"1988","journal-title":"Cancer Res"},{"issue":"20","key":"2020011209063885700_usz049C10","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/jnci\/djn329","article-title":"Prospective evaluation of risk factors for male breast cancer","volume":"100","author":"Brinton","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2020011209063885700_usz049C11","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJM199609123351116","article-title":"Gynecomastia and breast cancer during finasteride therapy","volume":"335","author":"Green","year":"1996","journal-title":"N Engl J Med"},{"issue":"4","key":"2020011209063885700_usz049C12","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/jnci\/djh062","article-title":"Male breast cancer during finasteride therapy","volume":"96","author":"Lee","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2020011209063885700_usz049C13","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/cam4.1273","article-title":"Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic countries","volume":"7","author":"Meijer","year":"2018","journal-title":"Cancer Med"},{"issue":"5","key":"2020011209063885700_usz049C14","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.juro.2013.04.132","article-title":"Male breast cancer and 5\u03b1-reductase inhibitors finasteride and dutasteride","volume":"190","author":"Bird","year":"2013","journal-title":"J Urol"},{"issue":"11","key":"2020011209063885700_usz049C15","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s10552-014-0455-6","article-title":"Long-term use of 5\u03b1-reductase inhibitors and the risk of male breast cancer","volume":"25","author":"Duijnhoven","year":"2014","journal-title":"Cancer Causes Control"},{"key":"2020011209063885700_usz049C16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/CLEP.S124674","article-title":"Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia","volume":"9","author":"Hagberg","year":"2017","journal-title":"Clin Epidemiol"},{"issue":"9","key":"2020011209063885700_usz049C17","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s10552-015-0622-4","article-title":"5-\u03b1 reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer","volume":"26","author":"Robinson","year":"2015","journal-title":"Cancer Causes Control"},{"issue":"4","key":"2020011209063885700_usz049C18","doi-asserted-by":"crossref","first-page":"T161","DOI":"10.1530\/ERC-14-0243","article-title":"Complexities of androgen receptor signaling in breast cancer","volume":"21","author":"McNamara","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"2020011209063885700_usz049C19","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1210\/me.2012-1107","article-title":"Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?","volume":"26","author":"Hickey","year":"2012","journal-title":"Mol Endocrinol"},{"issue":"2","key":"2020011209063885700_usz049C20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1010639429207","article-title":"Second primary breast cancer in men","volume":"66","author":"Dong","year":"2001","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"2020011209063885700_usz049C21","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/jnci\/94.17.1330","article-title":"Risk of subsequent cancer following breast cancer in men","volume":"94","author":"Auvinen","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"2020011209063885700_usz049C22","first-page":"855","article-title":"Epidemiology of contralateral breast cancer","volume":"8","author":"Chen","year":"1999","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"2020011209063885700_usz049C23","doi-asserted-by":"crossref","first-page":"R10","DOI":"10.1186\/bcr1643","article-title":"Risk of second primary cancer in men with breast cancer","volume":"9","author":"Satram-Hoang","year":"2007","journal-title":"Breast Cancer Res"},{"issue":"7","key":"2020011209063885700_usz049C24","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/sj.bjc.6602505","article-title":"Second primary malignancies in patients with male breast cancer","volume":"92","author":"Hemminki","year":"2005","journal-title":"Br J Cancer"},{"issue":"3","key":"2020011209063885700_usz049C25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/1754-9485.12542","article-title":"Case report of male breast cancer detected on magnetic resonance imaging","volume":"61","author":"Ryu","year":"2017","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"3","key":"2020011209063885700_usz049C26","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<629::AID-CNCR13>3.0.CO;2-V","article-title":"Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955\u20131996","volume":"85","author":"Goss","year":"1999","journal-title":"Cancer"},{"issue":"3","key":"2020011209063885700_usz049C27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0960-9776(96)90058-2","article-title":"A review of the management of the male breast carcinoma based on an analysis of 420 treated cases","volume":"5","author":"Ribeiro","year":"1996","journal-title":"Breast"},{"issue":"6","key":"2020011209063885700_usz049C28","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1524-4741.2009.00818.x","article-title":"The significance of nipple discharge of the male breast","volume":"15","author":"Morrogh","year":"2009","journal-title":"Breast J"},{"issue":"5","key":"2020011209063885700_usz049C29","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00428-006-0305-3","article-title":"Invasive carcinomas of the male breast: a morphologic study of the distribution of histologic subtypes and metastatic patterns in 778 cases","volume":"449","author":"Burga","year":"2006","journal-title":"Virchows Arch"},{"key":"2020011209063885700_usz049C30","doi-asserted-by":"crossref","first-page":"45293","DOI":"10.1038\/srep45293","article-title":"Characterisation of male breast cancer: a descriptive biomarker study from a large patient series","volume":"7","author":"Humphries","year":"2017","journal-title":"Sci Rep"},{"issue":"10","key":"2020011209063885700_usz049C31","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"2020011209063885700_usz049C32","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ijrobp.2013.07.016","article-title":"Management of male breast cancer in the United States: a surveillance, epidemiology and end results analysis","volume":"87","author":"Fields","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2020011209063885700_usz049C33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10549-018-4830-y","article-title":"Evolving surgical treatment decisions for male breast cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database","volume":"171","author":"Elmi","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"2020011209063885700_usz049C34","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1634\/theoncologist.10-7-471","article-title":"A review of the diagnosis and management of male breast cancer","volume":"10","author":"Giordano","year":"2005","journal-title":"Oncologist"},{"issue":"1","key":"2020011209063885700_usz049C35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5152\/ejbh.2017.3841","article-title":"Managing male mammary maladies","volume":"14","author":"Fentiman","year":"2018","journal-title":"Eur J Breast Health"},{"issue":"11","key":"2020011209063885700_usz049C36","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/cncr.21526","article-title":"Adjuvant systemic therapy for male breast carcinoma","volume":"104","author":"Giordano","year":"2005","journal-title":"Cancer"},{"issue":"3","key":"2020011209063885700_usz049C37","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<629::AID-CNCR13>3.0.CO;2-V","article-title":"Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955\u20131996","volume":"85","author":"Goss","year":"1999","journal-title":"Cancer"},{"issue":"3","key":"2020011209063885700_usz049C38","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.critrevonc.2009.04.002","article-title":"Male breast cancer evolution of treatment and prognostic factors Analysis of 489 cases","volume":"73","author":"Cutuli","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"2020011209063885700_usz049C39","doi-asserted-by":"crossref","first-page":"771","DOI":"10.7326\/0003-4819-117-9-771","article-title":"Carcinoma of the male breast","volume":"117","author":"Jaiyesimi","year":"1992","journal-title":"Ann Intern Med"},{"issue":"6","key":"2020011209063885700_usz049C40","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0748-7983(98)93608-3","article-title":"Male breast cancer: a 22-year experience","volume":"24","author":"Yildirim","year":"1998","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"2020011209063885700_usz049C41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3816\/CBC.2011.n.007","article-title":"Use of tamoxifen with postsurgical irradiation may improve survival in estrogen and progesterone receptor-positive male breast cancer","volume":"11","author":"Fogh","year":"2011","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"2020011209063885700_usz049C42","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1245\/s10434-009-0327-6","article-title":"Men with breast cancer have same disease-specific and event-free survival as women","volume":"16","author":"Marchal","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"2020011209063885700_usz049C43","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10549-011-1856-9","article-title":"A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences","volume":"133","author":"Shaaban","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2020011209063885700_usz049C44","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s12032-011-9978-9","article-title":"Outcome of non-metastatic male breast cancer: 118 patients","volume":"29","author":"Arslan","year":"2012","journal-title":"Med Oncol"},{"issue":"1","key":"2020011209063885700_usz049C45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000360793","article-title":"The 21-gene recurrence score assay (Oncotype DX\u2122) in estrogen receptor-positive male breast cancer: experience in an Israeli cohort","volume":"87","author":"Grenader","year":"2014","journal-title":"Oncology"},{"issue":"2","key":"2020011209063885700_usz049C46","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10549-016-3926-5","article-title":"21-gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010\u20132013","volume":"159","author":"Parsons","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2020011209063885700_usz049C47","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-40618-3","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017","edition":"8th ed"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/milmed\/article-pdf\/184\/9-10\/e581\/31799109\/usz049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/milmed\/article-pdf\/184\/9-10\/e581\/31799109\/usz049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T10:32:34Z","timestamp":1721125954000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/184\/9-10\/e581\/5425727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":47,"journal-issue":{"issue":"9-10","published-online":{"date-parts":[[2019,4,2]]},"published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usz049","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"type":"print","value":"0026-4075"},{"type":"electronic","value":"1930-613X"}],"subject":[],"published-other":{"date-parts":[[2019,9]]},"published":{"date-parts":[[2019,4,2]]}}}